GSK Regulatory Update Avodart (dutasteride)
Links shared publicly online about this topic.
- 1,277total visits
GSK Regulatory Update Avodart (dutasteride)
View full resource at medicalnewstoday.com
Tags: Prostate Cancer, Prostate, Benign Prostatic Hypertrophy Medication, Drug, Pharma, Men's Health, Avodart, GlaxoSmithKline
Most Recently Shared on March 30, 2010 at 5:18 pm By:
GSK Regulatory Update Avodart (dutasteride) http://mnt.to/3zBF #pharma #pharmaceutical
Also Shared By:
GlaxoSmithKline drops Avodart for prostate cancer risk reduction - Pharmaceutical and Biotechnology News - Pharma Letter
thepharmaletter.com — “UK pharma giant GlaxoSmithKline (LSE: GSK) says that it will no longer pursue global approval for the use of Avodart (dutasteride) to reduce the risk of prostate cancer. The company will withdraw applications from regulatory review where procedures are on” View full resource at thepharmaletter.com
Most Recently Shared on March 24, 2011 at 5:35 pm By:
GlaxoSmithKline drops Avodart for prostate cancer risk reduction http://bit.ly/gRCa25
GSK Regulatory Update: Avodart
us.gsk.com — “not named” View full resource at us.gsk.com
Most Recently Shared on November 23, 2009 at 3:11 pm By:
eyeonfda Pharma and Health Lawyer
GSK withdraws sNDA for Avodart for prostate cancer prevention http://ow.ly/ET4W
Advertisement
MNT Prostate News
@mnt_prostate
GSK Regulatory Update Avodart (dutasteride) http://mnt.to/3zBF #prostate
1 year ago...